Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients.
[heparin-induced thrombocytopenia]
Platelet
factor
4
/
heparin
(
PF
4
/
H
)
antibody
detection
is
widely
used
to
evaluate
the
risk
of
thrombosis
in
patients
undergoing
hemodialysis
(
HD
)
.
Most
patients
who
are
PF
4
/
H-
antibody-
positive
can
survive
thrombosis
,
but
the
reason
has
not
been
clarified
.
In
addition
,
no
valid
preventive
methods
for
thrombosis
in
patients
undergoing
HD
have
been
confirmed
.
A
single
-center
,
semi-randomized
controlled
study
was
designed
.
In
total
,
157
patients
fulfilled
the
inclusion
criteria
and
participated
.
Patients
were
first
divided
according
to
PF
4
/
H
antibody
detection
and
then
subdivided
randomly
according
to
different
anti-
platelet
agent
descriptions
.
(
1
)
PF
4
/
H
antibody-
positive
patients
suffered
a
significantly
higher
incidence
of
thrombosis
than
those
who
were
antibody-negative
;
(
2
)
PF
4
/
H
antibody-
positive
patients
who
survived
a
thrombosis
manifested
a
significantly
longer
bleeding
time
and
decreased
maximum
percentage
of
platelet
aggregation
inhibition
;
(
3
)
aspirin
and
clopidogrel
decreased
the
incidence
of
thrombosis
in
PF
4
/
H
antibody-
positive
patients
by
inhibiting
platelet
activation
.
The
PF
4
/
H
antibody
was
effective
for
prediction
of
the
risk
of
thrombosis
,
except
in
patients
with
dysfunctional
platelets
;
aspirin
manifested
effects
similar
to
clopidogrel
in
terms
of
prevention
of
thromboses
in
PF
4
/
H
antibody-
positive
patients
,
but
costs
much
less
and
is
therefore
recommended
.
